In our group, we study the mechanisms of action of monoclonal antibodies that are targeting cancer cells. We also study the mechanism of resistance towards these biomolecules in order to increase the activity of therapies based on monoclonal antibodies in patients with hematological malignancies or solid tumors.
The Anticancer Antibodies team, composed by medical doctors, post-docs, students and technicians, possess and expertise in the field of preclinical in vitro and in vivo modeling, as well as in the identification and the validation of predictive or prognostic factors in clinical samples and the development of new compounds or new therapeutic strategies. Our work is focused on monoclonal antibodies used in the treatment of hematological malignancies or breast cancer.
We explore the nature and the role of effector cells implicated in the antitumoral activity of these monoclonal antibodies, in addition to the role of the cells of the micro-environment such as adipocytes. We also search for new apoptotic signaling pathways induced by antibodies in the cancer cells, we develop new strategies for sensitization of cancer cells to monoclonal antibodies, and we evaluate the clinical relevance of observations made in preclinical models.